Across TCGA pan-cancer cohorts, RPL18P1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL18P1’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL18P1 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL18P1 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.
BRCA and COAD are the cancer types where RPL18P1 tumor–normal differential expression is most reproducible.